Clinical Trial Update: Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing immunogenicity and safety of Verorab in a one-week intradermal post-exposure prophylaxis regimen for rabies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• Verorab (rabies vaccine (inactivated))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Rabies | Phase 3 | Status: COMPLETED